Dr Chris Burns, the CEO of NOVONIX Limited (ASX:NVX), shares details on a significant supply agreement with Stellantis for synthetic graphite, a milestone for the North American battery market.
Copyright 2024 – Finance News Network
Source: Finance News Network
26 Mar 2025 - The pros and cons of lithium and CERENERGY grid storage batteries
Read More01 Jul 2021 - SUDA Pharmaceuticals Limited (ASX:SUD) CEO & Managing Director Dr Michael Baker discusses the company's acquisition of the invariant natural killer T (iNKT) cell therapy platform from Imperial College London.
Read More21 Sep 2023 - Brendan Stats - CEO - TMK Energy Limited (ASX:TMK) is a gas exploration company listed on the Australian Stock Exchange. TMK holds a 67% interest in the Gurvantes XXXV Project located in the South Gobi Basin of Mongolia and also holds a 20% interest in the Talisman Depp Project containing the Napoleon Structure located in the Barrow-Dampier Sub-basin.
Read More10 Oct 2023 - Harry Fisher - Project Manager - Benchmark’s prices and data empowers clients: from critical mineral contracts to EV battery supply chain investments and government policy.
Read More18 Nov 2020 - Shaw and Partners Chief Investment Officer Martin Crabb discusses to the current economic climate, inflation, and government and central bank reactions.
Read More20 Mar 2024 - Dotz Nano Limited (ASX:DTZ) CEO Sharon Malka discusses development of Dotz Earth, a new-generation sorbent technology for carbon dioxide capture.
Read More11 Mar 2021 - Rural Funds Group Limited (ASX:RFF) General Manager - Investor Relations and Marketing, James Powell, presents on the group's HY21 results.
Read More12 Apr 2024 - A pre-IPO interview with Cameron Woodrow, the Executive Director and CEO of Far Northern Resources Limited (ASX:FNR). Mr Woodrow discusses development of the company's three gold and base metals projects in the Northern Territory and north Queensland.
Read More06 Sep 2021 - Rural Funds Group (ASX:RFF) General Manager - Investor Relations and Marketing James Powell presents on the group's FY21 results.
Read More13 Mar 2020 - SUDA Pharmaceuticals Limited (ASX:SUD) CEO, Dr Michael Baker talks 1H20 results progress with the company's lead product Zolpimist, the spay version of Sanofi’s blockbuster insomnia drug Ambien and focus for 2020.
Read More
